SEC Form 4 · accession 0001127602-18-018570
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Mr. Ryding
Officer — EVP, Global Manufacturing
Period of report
Oct 20, 2016
Accepted (ET)
May 23, 2018 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 20, 2016 | S | 351 | $34.16 | D | 19,325 | D | |
| Common StockF2 | Jan 13, 2017 | F | 3,303 | $40.32 | D | 16,022 | D | |
| Common StockF1,F2 | Oct 20, 2017 | S | 346 | $45.70 | D | 15,676 | D | |
| Common StockF1,F2 | Oct 25, 2017 | S | 267 | $46.76 | D | 15,409 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2This number includes unvested restricted stock units previously reported.